非小细胞肺癌市场 - 全球产业规模、份额、趋势、机会及预测（按类型、疗法、药物类别、最终用户、地区和竞争格局划分，2021-2031年）

全球非小细胞肺癌市场预计将从 2025 年的 200.2 亿美元成长到 2031 年的 368.6 亿美元，复合年增长率为 10.71%。

该市场涵盖治疗性介入技术的研发和商业化，例如手术、放射线治疗、化疗和标靶免疫疗法，旨在治疗最常见的肺癌类型。推动市场成长的关键因素包括全球人口快速老化以及持续存在的呼吸系统风险因素，例如吸烟和环境污染。此外，针对特定基因突变的精准药物获得快速监管核准，显着增加了可治疗患者的数量，从而提升了行业收入。

根据世界卫生组织（世卫组织）的数据，肺癌仍将是全球癌症相关死亡的主要原因，也是最常见的恶性肿瘤，预计2024年新增病例将达到约250万例。儘管临床需求庞大，但由于先进的生物製剂和标靶治疗价格高昂，市场面临许多障碍。高昂的价格往往导致严格的报销政策，并限制了开发中国家的用药途径，从而限制了製药公司的获利潜力。

市场驱动因素

免疫疗法和标靶治疗的快速发展正在改变整个产业的临床疗效和收入模式。製药公司正优先推出抑制特定分子路径（例如EGFR突变和PD-L1表达）的药物，从而将标准治疗方案从广谱化疗转向精准肿瘤学。这种向精准肿瘤学的转变使得高价策略和更长的疗程成为可能，直接提升了产业价值。例如，Astra Zeneca在2024年2月的财务报告中宣布，其标靶肺癌药物泰瑞沙（Tagrisso）的收入成长了9%，达到58亿美元，这充分展现了特异性抑制剂市场的商业性实力。

此外，人口老化和环境因素导致恶性肿瘤发生率持续高涨，预计将推动对这些先进治疗方法的持续需求。儘管采取了预防措施，新增病例数量庞大，仍需要持续的诊断和治疗资源。美国癌症协会预测，2024年1月美国将新增约234,580例肺癌和支气管癌病例，凸显了普及治疗方法的紧迫性。为了充分利用不断成长的患者群体，主要企业正在积极进行策略性收购。例如，百时美施贵宝公司于2024年以48亿美元的股票价值完成了对Mirati Therapeutics的收购，旨在透过引入新型肺癌治疗产品来丰富其癌症治疗产品组合。

市场挑战

新型生物製药和标靶治疗的高昂成本是全球非小细胞肺癌市场成长的主要障碍。治疗费用往往超出医疗支付者和患者的负担能力，尤其是在经济资源有限的地区。这种差距迫使保险公司实施严格的报销政策，从而限制了病患获得先进医疗服务的机会。因此，製药公司面临市场渗透率低、产生收入受限的困境，因为很大一部分目标族群无法获得这些必要的治疗。

这种可近性差距直接影响产业绩效，导致潜在患者群体获得的治疗设备数量减少。当经济障碍阻碍治疗启动时，市场实际上会萎缩。根据美国肺臟协会统计，2024年美国确诊的肺癌患者中，约有20.9%无法接受治疗。这项数据表明，由于经济负担和保险覆盖范围的限制，大量患者群体未能被市场覆盖，导致临床需求无法转化为商业交易，阻碍了整体经济成长。

市场趋势

在辅助性治疗和辅助性治疗中采用免疫疗法的策略转变正在重塑市场动态，使高价值疗法得以在疾病早期阶段应用。临床医生越来越多地使用免疫查核点抑制剂来预防可切除肿瘤的復发，从而扩大了目标患者群体，并使治疗范围超越了转移性病例。这种发展趋势使製造商能够从转移前患者身上创造价值，显着提高收入潜力。例如，默克公司报告称，截至2024年10月，Keytruda的全球销售额增长了21%，达到74亿美元，并将这一增长归功于其在早期适应症（尤其是可切除的非小细胞肺癌）中应用的不断广泛。

同时，针对HER2和TROP2标记的抗体药物复合体（ADC）的快速崛起，正为抗药性肿瘤的治疗树立新的标准。这些先进的生物製药可将细胞毒性药物直接递送至癌细胞，并日益取代传统化疗，用于治疗初始标靶治疗后病情进展的患者。随着疗效数据的累积和符合监管核准的患者群体不断扩大，该领域正经历爆炸式的商业性化应用。根据Astra Zeneca截至2024年11月的财年数据，其针对HER2的ADC药物Enhertu在前九个月的全球年销售额达到27亿美元，显示这种创新疗法正迅速渗透市场。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球非小细胞肺癌市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（腺癌、鳞状细胞癌、大细胞癌）
  • 治疗方法（化疗、免疫疗法、放射线治疗、手术、标靶治疗）
  • 依药物类别（血管新生抑制剂、表皮生长因子受体阻断剂、激酶抑制剂、微管稳定剂、抗叶酸剂、PD-1/PD-L1抑制剂）
  • 依最终使用者（医院、诊所、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美非小细胞肺癌市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲非小细胞肺癌市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区非小细胞肺癌市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲非小细胞肺癌市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲非小细胞肺癌市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球非小细胞肺癌市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayar Healthcare AG
• Eli Lilly & Co.
• Biogen Inc
• Merck & Co
• AbbVie Inc
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc
• Avid Bioservices Inc
• Blueprint Medicines Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Non-Small Cell Lung Cancer Market is projected to expand from USD 20.02 Billion in 2025 to USD 36.86 Billion by 2031, reflecting a CAGR of 10.71%. This market encompasses the development and commercialization of therapeutic interventions, such as surgery, radiation, chemotherapy, and targeted immunotherapies, specifically aimed at treating the most common form of lung cancer. Key factors propelling growth include a rapidly aging global population and the persistence of respiratory risk factors like smoking and environmental pollution. Additionally, the expedited regulatory approval of precision medicines targeting specific genetic mutations is notably increasing the number of treatable patients and bolstering industry revenues.

According to the World Health Organization, lung cancer remained the leading cause of cancer-related mortality and the most frequently diagnosed malignancy globally in 2024, with approximately 2.5 million new cases. Despite this massive clinical demand, the market faces significant hurdles due to the high costs associated with advanced biologic and targeted therapies. These expensive price points often lead to strict reimbursement policies and restricted access in developing nations, limiting the revenue potential for pharmaceutical manufacturers.

Market Driver

The rapid evolution of immunotherapy and targeted therapeutics is transforming clinical results and revenue models within the industry. Pharmaceutical developers are prioritizing the launch of agents that block specific molecular pathways, such as EGFR mutations and PD-L1 expressions, shifting the standard of care away from broad-spectrum chemotherapy. This move toward precision oncology enables premium pricing strategies and longer treatment durations, which directly enhance industry value. For instance, AstraZeneca reported in its February 2024 results that revenue for the targeted lung cancer therapy Tagrisso rose by 9% to $5.8 billion, demonstrating the significant commercial strength of specialized inhibitors globally.

Furthermore, the persistently high rates of malignant neoplasms, fueled by aging populations and environmental exposure, ensure a steady demand for these advanced interventions. Despite prevention efforts, the sheer volume of new cases requires continuous diagnostic and therapeutic resources. The American Cancer Society projected in January 2024 that approximately 234,580 new lung and bronchus cancer cases would be diagnosed in the United States, highlighting the urgent need for accessible treatments. To leverage this growing patient base, major companies are pursuing strategic acquisitions; for example, Bristol Myers Squibb finalized the acquisition of Mirati Therapeutics in 2024 for an equity value of $4.8 billion to diversify its oncology portfolio with new lung cancer assets.

Market Challenge

The substantial expense linked to new biologic and targeted therapies represents a major obstacle to the growth of the Global Non-Small Cell Lung Cancer Market. High treatment costs often surpass the financial limits of healthcare payers and patients, particularly in areas with constrained economic resources. This disparity compels insurance providers to implement rigorous reimbursement policies, thereby limiting patient access to advanced care. As a result, pharmaceutical manufacturers encounter reduced market penetration because a large portion of the eligible population cannot afford these essential treatments, creating a bottleneck in revenue generation.

This gap in accessibility directly affects industry performance by lowering the volume of therapeutic units sold to the potential patient pool. When financial hurdles prevent the initiation of treatment, the market effectively shrinks. According to the American Lung Association, approximately 20.9% of diagnosed lung cancer cases in the United States received no treatment in 2024. This statistic highlights a significant portion of the patient population that remains uncaptured by the market, largely due to affordability issues and coverage restrictions, preventing the conversion of clinical demand into commercial transactions and hindering overall financial growth.

Market Trends

A strategic shift involving the use of immunotherapy regimens in neoadjuvant and adjuvant settings is reshaping market dynamics by introducing high-value treatments at earlier disease stages. Clinicians are increasingly utilizing immune checkpoint inhibitors for resectable tumors to prevent recurrence, which broadens the addressable patient base and extends treatment beyond metastatic cases. This evolution enables manufacturers to generate value from patients prior to metastasis, significantly boosting revenue potential. For example, Merck & Co., Inc. reported in October 2024 that global sales of Keytruda increased by 21% to $7.4 billion, a rise explicitly attributed to greater adoption in earlier-stage indications, specifically resectable non-small cell lung cancer.

Simultaneously, the rapid rise of Antibody-Drug Conjugates (ADCs) targeting HER2 and TROP2 markers is establishing a new standard of care for resistant tumors. These sophisticated biologics deliver cytotoxic agents directly to cancer cells, displacing traditional chemotherapy in various treatment lines for patients who progress after initial targeted therapies. This segment is witnessing explosive commercial adoption as efficacy data matures and regulatory approvals cover wider patient groups. According to AstraZeneca's November 2024 results, combined global sales of the HER2-directed ADC Enhertu reached $2.7 billion in the first nine months of the year, highlighting the swift market penetration of this innovative therapeutic approach.

Key Market Players

• Bayar Healthcare AG
• Eli Lilly & Co.
• Biogen Inc
• Merck & Co
• AbbVie Inc
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc
• Avid Bioservices Inc
• Blueprint Medicines Company

Report Scope

In this report, the Global Non-Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Small Cell Lung Cancer Market, By Type

• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma

Non-Small Cell Lung Cancer Market, By Treatment

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• Targeted Therapy Drugs

Non-Small Cell Lung Cancer Market, By Drug Class

• Angiogenesis Inhibitor
• Epidermal Growth Factor Receptor Blocker
• Kinase Inhibitor
• Microtubule Stabilizer
• Folate Antimetabolites
• PD-1/ PD-L1 Inhibitor

Non-Small Cell Lung Cancer Market, By End-User

• Hospitals & Clinics
• Others

Non-Small Cell Lung Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Small Cell Lung Cancer Market.

Available Customizations:

Global Non-Small Cell Lung Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Small Cell Lung Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)
  • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs)
  • 5.2.3. By Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor)
  • 5.2.4. By End-User (Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Non-Small Cell Lung Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Drug Class
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Small Cell Lung Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Non-Small Cell Lung Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Non-Small Cell Lung Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By End-User

7. Europe Non-Small Cell Lung Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Drug Class
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Small Cell Lung Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Non-Small Cell Lung Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Non-Small Cell Lung Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Non-Small Cell Lung Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Drug Class
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Non-Small Cell Lung Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Drug Class
      • 7.3.5.2.4. By End-User

8. Asia Pacific Non-Small Cell Lung Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Drug Class
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Small Cell Lung Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Non-Small Cell Lung Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Non-Small Cell Lung Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Non-Small Cell Lung Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Drug Class
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Non-Small Cell Lung Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Drug Class
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Non-Small Cell Lung Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Drug Class
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Small Cell Lung Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Non-Small Cell Lung Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Non-Small Cell Lung Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By End-User

10. South America Non-Small Cell Lung Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Drug Class
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Small Cell Lung Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Drug Class
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Non-Small Cell Lung Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Drug Class
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Non-Small Cell Lung Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Drug Class
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Small Cell Lung Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayar Healthcare AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Eli Lilly & Co.
• 15.3. Biogen Inc
• 15.4. Merck & Co
• 15.5. AbbVie Inc
• 15.6. AstraZeneca PLC
• 15.7. Novartis AG
• 15.8. Pfizer Inc
• 15.9. Avid Bioservices Inc
• 15.10. Blueprint Medicines Company

16. Strategic Recommendations

17. About Us & Disclaimer